INS and type 2 diabetes mellitus: The subjects were representative for patients with Type 2 diabetes starting on basal insulin therapy, with disease duration of 9.5 years, HbA1c above target [67 mmol/mol (8.3%)] and moderate obesity (BMI 25–33 kg/m2).